Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Devyser Diagnostics AB (publ) (DVYSR.ST)
Hägersten, SE
Headquartered in Hägersten, Sweden, and established in 2004, Devyser Diagnostics AB (publ) specializes in the development, manufacturing, and global sale of advanced diagnostic kits and solutions for DNA testing. The company's innovative products are crucial for genetic analysis in key medical areas, including hereditary diseases, oncology, and post-transplantation monitoring. Devyser offers a broad array of diagnostic tools, covering applications such as post-transplant management, thalassemia screening, and the detection of various cancers like breast, colorectal, and ovarian. Their portfolio also extends to non-invasive fetal RHD screening, diagnostics for inherited conditions, cystic fibrosis, cardiovascular issues, male infertility, and rapid aneuploidy analysis, complemented by essential accessories. These solutions are utilized for diverse purposes, from diagnosing genetic disorders and guiding targeted cancer treatments to ensuring thorough follow-up care for transplant patients. Furthermore, Devyser provides specialized software programs, including Amplicon Suite and Advyser, which facilitate the processing, analysis, and interpretation of test results, enabling efficient marker screening and patient sample tracking. The company's operations span Sweden, the broader European market, the Middle East, Africa, North and South America, and Asia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.11% | -5.20% | -1.06% | +3.10% | -17.99% | -18.13% | -11.60% | +14.53% | +4.49% | +4.49% | +4.49% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%+15.5% ★ Q1'26: +12.8% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%+86.4% ★ Q1'26: +113.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%-1.8% Q1'26: +19.1% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+4.2% Q1'26: +4.5% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%+2.9% Q1'26: +2.2% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%+1.2% Q1'26: +0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×2.37× Q1'26: 1.19× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 3 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
93.48M
est: 91.90M (+1.7%)
|
126.61M
est: 127.30M (-0.5%)
|
169.30M
est: 169.46M (-0.1%)
|
216.90M
est: 217.78M (-0.4%)
|
250.50M
est: 254.80M (-1.7%)
|
300.67M
285.24M – 310.93M
+18.0% YoY
|
372.33M
343.15M – 388.87M
+23.8% YoY
|
453.33M
453.19M – 453.48M
+21.8% YoY
|
| EBITDA |
-18.05M
est: -19.58M (+7.8%)
|
-46.02M
est: -27.12M (-69.7%)
|
-43.80M
est: -36.10M (-21.3%)
|
-31.20M
est: -35.22M (+11.4%)
|
37.70M
est: -41.21M (+191.5%)
|
-48.63M
-50.29M – -46.13M
-18.0% YoY
|
-60.22M
-62.89M – -55.50M
-23.8% YoY
|
-73.32M
-73.34M – -73.29M
-21.8% YoY
|
| EBIT |
-20.97M
est: -25.31M (+17.2%)
|
-52.20M
est: -35.06M (-48.9%)
|
-53.60M
est: -46.67M (-14.9%)
|
-54.10M
est: -51.55M (-4.9%)
|
10.60M
est: -60.31M (+117.6%)
|
-71.17M
-73.60M – -67.52M
-18.0% YoY
|
-88.13M
-92.05M – -81.23M
-23.8% YoY
|
-107.31M
-107.34M – -107.27M
-21.8% YoY
|
| Net Income |
-20.73M
est: -9.84M (-110.7%)
|
-45.95M
est: -42.47M (-8.2%)
|
-53.60M
est: -38.86M (-37.9%)
|
-61.50M
est: -59.95M (-2.6%)
|
-8.40M
est: -13.81M (+39.2%)
|
40.91M
36.01M – 43.64M
+396.3% YoY
|
76.50M
65.08M – 88.50M
+87.0% YoY
|
120.60M
97.24M – 144.55M
+57.7% YoY
|
| SGA |
75.65M
est: 79.89M (-5.3%)
|
132.07M
est: 110.66M (+19.3%)
|
163.50M
est: 147.30M (+11.0%)
|
193.10M
est: 191.65M (+0.8%)
|
173.30M
est: 224.24M (-22.7%)
|
264.60M
251.03M – 273.63M
+18.0% YoY
|
327.67M
301.99M – 342.23M
+23.8% YoY
|
398.96M
398.83M – 399.09M
+21.8% YoY
|
| EPS |
-1.85
est: -0.60 (-208.3%)
|
-2.89
est: -2.59 (-11.6%)
|
-3.31
est: -2.37 (-39.7%)
|
-3.75
est: -3.61 (-3.8%)
|
-0.51
est: -0.85 (+39.8%)
|
2.45
2.17 – 2.63
+389.4% YoY
|
4.58
3.92 – 5.33
+86.8% YoY
|
7.19
5.86 – 8.71
+57.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-28 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-27 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-26 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-25 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-20 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-13 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jan Wahlstrom | Chief Executive Officer | 3M | male |
| Camilla Wiberg | Chief Human Resource Officer | — | female |
| John Murad | Vice President & GM of Devyser US | — | male |
| Michael Uhlin | Chief Scientific Officer | — | male |
| Sabina Berlin | Chief Financial Officer | — | female |
| Theis Kipling | Chief Commercial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DVYSR.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
